
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **August, 2017**

Commission File Number: **001-36187**

EVOGENE LTD.

(Translation of Registrant's Name into English)

**13 Gad Feinstein Street
Park Rehovot P.O.B 2100
Rehovot 7612002 Israel**
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

CONTENTS

Attached hereto and incorporated by reference herein are the following exhibits:

- 99.1 Press Release: Evogene Reports Second Quarter 2017 Financial Results.
- 99.2 Presentation Regarding DuPont Pioneer–Evogene Collaboration for the Development of Bio-stimulant Corn Products.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.
(Registrant)

Date: August 10, 2017

By: /s/ Alex Taskar

Alex Taskar
Chief Financial Officer

EXHIBIT INDEX

| <u>EXHIBIT NO.</u> | <u>DESCRIPTION</u> |
|-----------------------------|--|
| <u>99.1</u> | <u>Press Release: Evogene Reports Second Quarter 2017 Financial Results.</u> |
| <u>99.2</u> | <u>Presentation Regarding DuPont Pioneer–Evogene Collaboration for the Development of Bio-stimulant Corn Products.</u> |

Evogene Reports Second Quarter 2017 Financial Results

Conference call and webcast, today at 9:00 am Eastern Time

Rehovot, Israel – August 10, 2017 – Evogene Ltd. (NASDAQ, TASE: EVGN), a leading company for the improvement of crop productivity and economics, announced today its financial results for the second quarter ended June 30, 2017.

Ofer Haviv, Evogene's President and CEO, stated: “2017 is proving to be a significant year in the development of Evogene and we look forward with high expectations to what the year has yet to bring. We were pleased to see progress and achievements in our collaborations and internal programs, across all areas of activities. In our on-going Fusarium collaboration with Monsanto, we reached an important milestone, and our newly initiated collaboration with DuPont-Pioneer¹, is a testament to the important achievements reached in our internal bio-stimulant product program. This collaboration is an example of the comprehensive abilities of our computational biology platform, which is constantly evolving to now also include ‘artificial intelligence’, allowing us to enter new areas of activity. Evogene continues to lead innovation and, as we announced in the past, we are actively seeking applications for our exciting technology, both within and outside the agriculture world.

For the first time, in addition to our robust internal programs, we now have collaborations with at least one world leading company in each of our areas of activity: DuPont-Pioneer in Ag-Biologicals, Monsanto in Seed Traits and BASF in Ag-Chemicals. We believe this trend will continue and are looking to strengthen our position as a world leading ag-biotech company with additional collaborations.

Looking deeper into each area of activity, I would like to emphasize the following:

In Ag-Biologicals, our most important achievement in recent months is our strategic collaboration with DuPont-Pioneer, a leader in the corn seeds market, for the development of bio-stimulant seed coating products. This collaboration is based on the achievements of an internal product program in which positive results were achieved in corn field trials under drought conditions. Additionally, we also have an internal bio-stimulant program in wheat in which we reached positive results on 1st year field trials on select microbial strains that will be re-validated in field trials next year. Bio-stimulants present an exciting opportunity, as product development is considered short, with time to market, according to industry estimates, as short as 5 years, depending on regulation.

¹ Please see Evogene DuPont-Pioneer collaboration presentation, filed together with this press release <http://www.evogene.com/wp-content/uploads/2017/07/evogene-dupont-presentation-final.pdf>

We are also happy to announce the addition of a product program for the development of microbial-based bio-pesticides that address various insect and fungi control. This market is expected to reach \$8B in 2020².

In **Seed Traits**, we had three important achievements during the past quarter:

- (i) Gene advancement in our disease resistance Fusarium collaboration with Monsanto - we reached an important milestone with Evogene discovered genes showing resistance to Fusarium in model plants, with the top prioritized genes advancing to testing in Monsanto's corn pipeline.
- (ii) Completion of discovery in our yield and abiotic stress collaboration with Monsanto - we successfully completed of the gene discovery phase, with the discovery of ~4,000 genes and more than 1,000 genes nominated to Monsanto's product development pipeline, as disclosed in the past.
- (iii) Advancement to phase I in our internal insect control program - in our Coleopteran control product program we have advanced a gene to phase I, having met all of phase advancement criteria, including efficacy and lower risk of toxicity to other organisms such as bees, animals and humans.

In **Ag-Chemicals**, we continue to show good progress in our internal herbicide program as well as in our collaboration with BASF. Additionally, I am very excited to disclose that we recently initiated an insecticide product program. The global insecticide market is currently estimated at \$14B, and is expected to reach \$16B by 2020³.

In conclusion, we are making important progress in all three of our core activity areas: Ag-Biologicals, Seed Traits and Ag-Chemicals. We look forward to the second half of 2017, and we expect progress in our internal programs, as well as our collaborations with world leading partners, and hope to forge new partnerships in the future."

Financial results for the period ending June 30, 2017

Cash Position: As of June 30, 2017, the Company had \$79.7 million in cash, short-term bank deposits and marketable securities, as compared to \$83.4 million at March 31, 2017. Evogene continues to expect that its net cash usage for full-year 2017 will be in the range of \$16 to \$18 million.

Revenues primarily consist of research and development payments, reflecting R&D cost reimbursement under certain of our collaboration agreements. The majority of these agreements also provide for development milestone payments and royalties or other forms of revenue sharing from successfully developed products.

² Dunham Trimmer (2015)

³ Phillips McDougall (2015)

Revenues for the first half of 2017 reached \$1.9 million in comparison to \$3.8 million, in the comparable period in 2016. Total revenues for the second quarter of 2017 were \$1.2 million, compared to \$1.8 million for the second quarter in 2016. The decline in revenues reflects the net decrease in research and development cost reimbursement, in accordance with the work plans under Evogene's various collaboration agreements. This decline is mainly due to the advancement of our collaboration agreement with Monsanto, from gene discovery to pre-development efforts, resulting in reduction of activity scope. As we look forward, we expect this revenue trend to continue.

During the first half of 2017 we saw a negative impact on our expenses due to the depreciation of the USD in comparison to the Israeli Shekel. Our expenses, mostly salaries, are denominated in Israeli Shekels while our reporting currency is USD.

Cost of revenues consist of collaboration related R&D expenses. Cost of revenues during the first half of 2017 reached \$1.7 million in comparison to \$3.1 million in first half of 2016. During the second quarter of 2017 the cost of revenues reached \$1.0 million, in comparison to \$1.6 million for the same period in 2016. The decrease related primarily to the decrease in revenues for such periods.

R&D expenses for the first half of 2017 reached \$8.0 million in comparison to \$7.8 million in the first half of 2016. During the second quarter of 2017, R&D expenses remained stable at \$4.0 million, in comparison to the second quarter of 2016. R&D expenses were impacted by exchange rate fluctuations, as mentioned above.

Operating loss during the first half of 2017 reached \$10.4 million, in comparison to a loss of \$9.8 million during the first half of 2016, due to the decrease in revenues which was partially offset by a decrease in other expense categories. Operating loss for the second quarter of 2017 remained stable at \$5.2 million in comparison to the comparable quarter in 2016.

The net financing income for the first half of 2017 reached \$0.8 million in comparison to \$1.9 million in the corresponding period. The net financing income for the second quarter of 2017 reached \$0.4 million in comparison to \$0.7 million in the comparable quarter in 2016. This decrease is due to relatively high capital gains derived from the company's marketable securities in the first and second quarter of 2016.

Net Loss for the first half of 2017 reached \$9.6 million in comparison to \$7.8 million in the first half of 2016. Net loss for the second quarter of 2017 was \$4.7 million compared to the net loss of \$4.5 million in the comparable quarter in 2016. The increase in the net loss was primarily due to the decrease in revenues and the decrease in net financing income, which was partially offset by a net decline in other expense categories.

Conference Call & Webcast Details:

Evogene management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or +972-3-918-0644 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com.

A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-254-7270 toll free from the United States, or +972-3-925-5940 internationally. The replay will be accessible through August 12, 2017, and an archive of the webcast will be available on the Company's website through August 20, 2017.

About Evogene Ltd.:

Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key target markets: improved seed traits (addressing yield increase, tolerance to environmental stresses and resistance to insects and diseases); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com.

Forward Looking Statements:

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Contact:

Nir Zalik
IR/PR Manager
E: IR@evogene.com
T: (+972)-8-931-1963

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

U.S. dollars in thousands (except share and per share data)

| | As of June 30, | | As of December 31, | |
|---|----------------|------------|--------------------|---------|
| | 2017 | | 2016 | |
| | Unaudited | Audited | Unaudited | Audited |
| CURRENT ASSETS: | | | | |
| Cash and cash equivalents | \$ 5,758 | \$ 5,533 | \$ 3,236 | \$ 47 |
| Restricted cash | 47 | 47 | 47 | 47 |
| Marketable securities | 65,878 | 74,801 | 71,738 | |
| Short-term bank deposits | 8,017 | 16,561 | 13,137 | |
| Trade receivables | 1,063 | 80 | 169 | |
| Other receivables | 1,058 | 1,542 | 1,163 | |
| | 81,821 | 98,564 | 89,490 | |
| LONG-TERM ASSETS: | | | | |
| Long-term deposits | 14 | 16 | 13 | |
| Property, plant and equipment, net | 5,611 | 7,354 | 6,483 | |
| | 5,625 | 7,370 | 6,496 | |
| | \$ 87,446 | \$ 105,934 | \$ 95,986 | |
| CURRENT LIABILITIES: | | | | |
| Trade payables | \$ 947 | \$ 1,364 | \$ 1,330 | |
| Other payables | 2,502 | 2,495 | 2,803 | |
| Liabilities in respect of government grants | 103 | 766 | 125 | |
| Deferred revenues and other advances | 1,081 | 820 | 967 | |
| | 4,633 | 5,445 | 5,225 | |
| LONG-TERM LIABILITIES: | | | | |
| Liabilities in respect of government grants | 3,416 | 2,614 | 3,303 | |
| Deferred revenues and other advances | 30 | 157 | 138 | |
| Severance pay liability, net | 32 | 30 | 31 | |
| | 3,478 | 2,801 | 3,472 | |
| SHAREHOLDERS' EQUITY: | | | | |
| Ordinary shares of NIS 0.02 par value: | | | | |
| Authorized - 150,000,000 ordinary shares; Issued and outstanding - 25,745,371, 25,447,024 and 25,480,809 shares at June 30, 2017 and 2016 and December 31, 2016, respectively | 142 | 140 | 141 | |
| Share premium and other capital reserve | 184,977 | 181,985 | 183,342 | |
| Accumulated deficit | (105,784) | (84,437) | (96,194) | |
| | 79,335 | 97,688 | 87,289 | |
| | \$ 87,446 | \$ 105,934 | \$ 95,986 | |

CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

U.S. dollars in thousands (except share and per share data)

| | Six months ended June 30, | | Three months ended June 30, | | Year ended December 31, | |
|--------------------------------------|------------------------------|------------|--------------------------------|------------|----------------------------|--|
| | 2017 | | 2016 | | 2016 | |
| | | | Unaudited | | | |
| Revenues | \$ 1,899 | \$ 3,824 | \$ 1,178 | \$ 1,808 | \$ 6,540 | |
| Cost of revenues | 1,665 | 3,090 | 1,018 | 1,575 | 5,639 | |
| Gross profit | 234 | 734 | 160 | 233 | 901 | |
| Operating expenses: | | | | | | |
| Research and development, net | 8,018 | 7,765 | 4,014 | 4,040 | 16,405 | |
| Business development | 821 | 790 | 370 | 428 | 1,696 | |
| General and administrative | 1,821 | 1,944 | 943 | 946 | 3,889 | |
| Total operating expenses | 10,660 | 10,499 | 5,327 | 5,414 | 21,990 | |
| Operating loss | (10,426) | (9,765) | (5,167) | (5,181) | (21,089) | |
| Financing income | 1,206 | 2,095 | 484 | 761 | 2,424 | |
| Financing expenses | (359) | (165) | (57) | (43) | (891) | |
| Loss before taxes on income | (9,579) | (7,835) | (4,740) | (4,463) | (19,556) | |
| Taxes on income | 11 | - | 3 | - | 36 | |
| Net loss | \$ (9,590) | \$ (7,835) | \$ (4,743) | \$ (4,463) | \$ (19,592) | |
| Basic and diluted net loss per share | \$ (0.37) | \$ (0.31) | \$ (0.18) | \$ (0.18) | \$ (0.77) | |

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

U.S. dollars in thousands

| | Share capital | Share premium and other capital reserve | Unaudited | | Total |
|---|------------------|---|------------------------|-----------|---------|
| | | | Accumulated deficit | | |
| Balance as of January 1, 2017 (audited) | \$ 141 | \$ 183,342 | \$ (96,194) | \$ 87,289 | |
| Net loss | - | - | (9,590) | | (9,590) |
| Exercise of options | 1 | 669 | - | | 670 |
| Share-based compensation | - | 966 | - | | 966 |
| Balance as of June 30, 2017 | \$ 142 | \$ 184,977 | \$ (105,784) | \$ 79,335 | |

| | Share capital | Share premium and other capital reserve | Unaudited | | Total |
|---|------------------|---|------------------------|------------|---------|
| | | | Accumulated deficit | | |
| Balance as of January 1, 2016 (audited) | \$ 140 | \$ 180,214 | \$ (76,602) | \$ 103,752 | |
| Net loss | - | - | (7,835) | | (7,835) |
| Exercise of options | *)- | 114 | - | | 114 |
| Share-based compensation | - | 1,657 | - | | 1,657 |
| Balance as of June 30, 2016 | \$ 140 | \$ 181,985 | \$ (84,437) | \$ 97,688 | |

*) Represents an amount lower than \$1

| | Share capital | Share premium and other capital reserve | Unaudited | | Total |
|-----------------------------|------------------|---|------------------------|-----------|---------|
| | | | Accumulated deficit | | |
| Balance as of April 1, 2017 | \$ 141 | \$ 184,206 | \$ (101,041) | \$ 83,306 | |
| Net loss | - | - | (4,743) | | (4,743) |
| Exercise of options | 1 | 321 | - | | 322 |
| Share-based compensation | - | 450 | - | | 450 |
| Balance as of June 30, 2017 | \$ 142 | \$ 184,977 | \$ (105,784) | \$ 79,335 | |

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

U.S. dollars in thousands

| | Share capital | Share premium and other capital reserve | Unaudited | | Total |
|-----------------------------|------------------|---|------------------------|------------|-------|
| | | | Accumulated deficit | | |
| Balance as of April 1, 2016 | \$ 140 | \$ 181,170 | \$ (79,974) | \$ 101,336 | |
| Net loss | - | - | (4,463) | (4,463) | |
| Exercise of options | *)- | 29 | - | 29 | |
| Share-based compensation | - | 786 | - | 786 | |
| Balance as of June 30, 2016 | \$ 140 | \$ 181,985 | \$ (84,437) | \$ 97,688 | |

*) Represents an amount lower than \$1

| | Share capital | Share premium and other capital reserve | Audited | | Total |
|---------------------------------|---------------|---|------------------------|------------|-------|
| | | | Accumulated deficit | | |
| Balance as of January 1, 2016 | \$ 140 | \$ 180,214 | \$ (76,602) | \$ 103,752 | |
| Net loss | - | - | (19,592) | (19,592) | |
| Exercise of options | 1 | 185 | - | 186 | |
| Share-based compensation | - | 2,943 | - | 2,943 | |
| Balance as of December 31, 2016 | \$ 141 | \$ 183,342 | \$ (96,194) | \$ 87,289 | |

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

| | Six months ended June 30, | | Three months ended June 30, | | Year ended December 31, 2016 | |
|---|------------------------------|------------|--------------------------------|------------|------------------------------------|---------|
| | 2017 | 2016 | 2017 | 2016 | 2016 | Audited |
| | Unaudited | | | | | |
| Cash flows from operating activities | | | | | | |
| Net loss | \$ (9,590) | \$ (7,835) | \$ (4,743) | \$ (4,463) | \$ (19,592) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | |
| Adjustments to the profit or loss items: | | | | | | |
| Depreciation | 1,091 | 1,176 | 546 | 585 | 2,279 | |
| Share-based compensation | 966 | 1,657 | 450 | 786 | 2,943 | |
| Net financing income | (1,089) | (2,017) | (524) | (723) | (1,688) | |
| Loss from sale of property, plant and equipment | - | 17 | - | 17 | 39 | |
| Taxes on income | 11 | - | 3 | - | 36 | |
| | 979 | 833 | 475 | 665 | 3,609 | |
| Changes in asset and liability items: | | | | | | |
| Decrease (increase) in trade receivables | (894) | 2,595 | (438) | 545 | 2,506 | |
| Decrease (increase) in other receivables | 50 | (477) | 770 | 291 | (100) | |
| Decrease (increase) in long-term deposits | (1) | 6 | (10) | - | 9 | |
| Increase (decrease) in trade payables | (319) | (241) | 110 | 54 | (215) | |
| Increase (decrease) in other payables | (299) | (596) | (656) | 160 | (303) | |
| Increase in severance pay liability, net | 1 | 4 | - | 4 | 5 | |
| Increase (decrease) in deferred revenues and other advances | 6 | 119 | (50) | - | (81) | |
| Increase in liabilities in respect of government grants | - | 115 | - | - | 115 | |
| | (1,456) | 1,525 | (274) | 1,054 | 1,936 | |
| Cash received (paid) during the period for: | | | | | | |
| Interest received | 1,121 | 1,154 | 450 | 475 | 2,360 | |
| Taxes paid | (11) | - | - | - | (6) | |
| Net cash used in operating activities | (8,957) | (4,323) | (4,092) | (2,269) | (11,693) | |

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

| | Six months ended June 30, | | Three months ended June 30, | | Year ended December 31, | |
|---|------------------------------|----------|--------------------------------|----------|----------------------------|---|
| | 2017 | | 2016 | | 2016 | |
| | | | Unaudited | | Audited | |
| <u>Cash flows from investing activities:</u> | | | | | | |
| Purchase of property, plant and equipment | \$ (285) | \$ (474) | \$ (87) | \$ (91) | \$ (808) | |
| Proceeds from sale of marketable securities | 11,115 | 11,624 | 4,829 | 8,134 | 23,926 | |
| Purchase of marketable securities | (5,327) | (13,750) | (2,623) | (8,465) | (24,561) | |
| Proceeds from bank deposits, net | 5,120 | 2,042 | 4,000 | 4,042 | 5,466 | |
| Proceeds from sale of property, plant and equipment | - | - | - | - | - | 5 |
| Net cash provided by (used in) investing activities | 10,623 | (558) | 6,119 | 3,620 | 4,028 | |
| <u>Cash flows from financing activities:</u> | | | | | | |
| Proceeds from exercise of options | 670 | 114 | 322 | 29 | 186 | |
| Proceeds from government grants | 266 | 258 | 165 | 150 | 802 | |
| Repayment of government grants | (144) | (199) | (50) | - | (333) | |
| Net cash provided by financing activities | 792 | 173 | 437 | 179 | 655 | |
| Exchange rate differences - cash and cash equivalent balances | 64 | 20 | 4 | 18 | 25 | |
| Increase (decrease) in cash and cash equivalents | 2,522 | (4,688) | 2,468 | 1,548 | (6,985) | |
| Cash and cash equivalents, beginning of the period | 3,236 | 10,221 | 3,290 | 3,985 | 10,221 | |
| Cash and cash equivalents, end of the period | \$ 5,758 | \$ 5,533 | \$ 5,758 | \$ 5,533 | \$ 3,236 | |
| <u>Significant non-cash transactions</u> | | | | | | |
| Acquisition of property, plant and equipment | \$ 109 | \$ 225 | \$ 53 | \$ 225 | \$ 150 | |



**Development of bio-stimulants
corn products**
DuPont Pioneer-Evogene collaboration

August, 2017

Collaboration goal

To develop and commercialize microbiome-based seed treatment
bio-stimulant products that improve corn yields




Collaboration 'at a glance'

- Multi-year development effort focused on increasing corn yields across multiple locations
- Leverages a set of already discovered, validated and optimized microbial strain teams
- Evogene will receive milestone payments and royalties from product sales
- DuPont Pioneer has exclusive licensing rights




Ag-biologicals market opportunity



*Data based on industry research

14

Collaboration Structure




Collaborating parties

| Evogene | DuPont Pioneer |
|---|--|
| <ul style="list-style-type: none">■ Leading biotechnology company for the improvement of crop productivity■ Proprietary predictive biology platform including artificial intelligence for research and development of ag-biologicals■ Downstream capabilities for formulation and fermentation to drive product development■ Discovered, validated and optimized microbial strain teams predicted to work as corn bio-stimulants | <ul style="list-style-type: none">■ World's leading developer and supplier of advanced plant genetics and insect, weed and disease control solutions■ Know-how on market needs and product definitions■ Broad field testing platform used to decrease time to market by early testing of promising candidates■ Access to market and proven track record of introducing new products |

Combining Evogene's innovative technology with DuPont Pioneer's product development expertise and access to markets sharply enhances the potential to benefit from the emerging field of microbiome-based bio stimulants

Discovery and development of bio-stimulants

Evogene's Approach



Summary

- Microbiome science has dramatically evolved in recent years, and holds a significant opportunity for improving crop productivity
- Collaboration focus is 'new generation' bio-stimulants based on microbials - delivering yield increases with low investments
- DuPont Pioneer and Evogene are well positioned to harness plant-microorganism interactions to drive crop productivity by leveraging biological understanding and big data capabilities through dedicated computational platforms
- As part of the collaboration, proven microbial strains discovered and validated by Evogene will be further developed by the parties for the goal of commercialization by DuPont Pioneer for corn



© 2018 DuPont



Thanks

August, 2017

